Pharming Group NV (PHAR) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Pharming Group NV stock (PHAR) is currently trading at $16.23. Pharming Group NV PE ratio is 399.25. Pharming Group NV PS ratio (Price-to-Sales) is 2.96. Analyst consensus price target for PHAR is $33.80. WallStSmart rates PHAR as Sell.
- PHAR PE ratio analysis and historical PE chart
- PHAR PS ratio (Price-to-Sales) history and trend
- PHAR intrinsic value — DCF, Graham Number, EPV models
- PHAR stock price prediction 2025 2026 2027 2028 2029 2030
- PHAR fair value vs current price
- PHAR insider transactions and insider buying
- Is PHAR undervalued or overvalued?
- Pharming Group NV financial analysis — revenue, earnings, cash flow
- PHAR Piotroski F-Score and Altman Z-Score
- PHAR analyst price target and Smart Rating
Pharming Group NV
📊 No data available
Try selecting a different time range
PHAR Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Pharming Group NV (PHAR)
PHAR trades 733% above its Graham fair value of $1.87, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Pharming Group NV (PHAR) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in eps growth. Concerns around return on equity and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Pharming Group NV (PHAR) Key Strengths (1)
Earnings per share surging 98.10% year-over-year
Supporting Valuation Data
Pharming Group NV (PHAR) Areas to Watch (8)
Very low returns on shareholder equity
Very thin margins with limited operational efficiency
Very thin margins, barely profitable
Very low institutional interest at 0.21%
Premium pricing at 3.9x book value
Small-cap company with higher risk but more growth potential
Revenue is fairly priced at 2.96x sales
Solid revenue growth at 14.90% per year
Supporting Valuation Data
Pharming Group NV (PHAR) Detailed Analysis Report
Overall Assessment
This company scores 39/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 3.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth. Growth metrics are encouraging with EPS Growth at 98.10%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.96), Price/Book (3.86) suggest expensive pricing. Growth concerns include Revenue Growth at 14.90%, which may limit upside. Profitability pressure is visible in Return on Equity at 1.02%, Operating Margin at 5.82%, Profit Margin at 0.76%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 1.02% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 14.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PHAR Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PHAR's Price-to-Sales ratio of 2.96x sits near its historical average of 3.32x (37th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 41% below its historical high of 4.99x set in Dec 2020, and 52% above its historical low of 1.95x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~1.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Pharming Group NV (PHAR) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Pharming Group NV operates as a stable business with moderate growth and solid fundamentals. Revenue reached 376M with 15% growth year-over-year. Profit margins are thin at 0.8%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 6M in free cash flow and 6M in operating cash flow. Earnings are translating into actual cash generation.
ROE of 1.0% suggests the company isn't efficiently converting equity into profits.
What to Watch Next
Margin expansion: can Pharming Group NV push profit margins above 15% as the business scales?
Valuation compression risk at a P/E of 399.3x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Pharming Group NV.
Bottom Line
Pharming Group NV offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:05:38 AM
About Pharming Group NV(PHAR)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Pharming Group NV, a specialty pharmaceutical company, develops products for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company is headquartered in Leiden, the Netherlands.